IPP Bureau

Kenvue collaborates with API to launch India’s first cough clinics
Kenvue collaborates with API to launch India’s first cough clinics

By IPP Bureau - July 18, 2025

Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough

Brenntag Specialties Pharma offering phosphate-based excipients by Budenheim
Brenntag Specialties Pharma offering phosphate-based excipients by Budenheim

By IPP Bureau - July 18, 2025

Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes

Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2
Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2

By IPP Bureau - July 18, 2025

The company is addressing these observations comprehensively

Concord Biotech announces successful completion EU GMP inspection at its API facility
Concord Biotech announces successful completion EU GMP inspection at its API facility

By IPP Bureau - July 18, 2025

This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty
Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

By IPP Bureau - July 17, 2025

Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru
Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru

By IPP Bureau - July 17, 2025

This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms

SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally
SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally

By IPP Bureau - July 17, 2025

The receipt of EIR reaffirms the company's commitment to maintaining global quality standards

Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US
Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US

By IPP Bureau - July 17, 2025

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva

Suven Life Sciences announces first patient randomized in Phase-2b clinical trial of Ropanicant
Suven Life Sciences announces first patient randomized in Phase-2b clinical trial of Ropanicant

By IPP Bureau - July 17, 2025

There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated

Corona Remedies acquires 7 brands from Bayer's pharma division in India
Corona Remedies acquires 7 brands from Bayer's pharma division in India

By IPP Bureau - July 17, 2025

This marks the fourth acquisition by Corona Remedies from multinational corporations

Emcure Pharmaceuticals, Sanofi India ink distribution agreement to broaden reach of Sanofi's oral anti-diabetic drugs
Emcure Pharmaceuticals, Sanofi India ink distribution agreement to broaden reach of Sanofi's oral anti-diabetic drugs

By IPP Bureau - July 17, 2025

Thermo Fisher Scientific to acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey
Thermo Fisher Scientific to acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey

By IPP Bureau - July 17, 2025

Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers

Cipla Health launches Astaberry's campaign 'Get the Rich Look'
Cipla Health launches Astaberry's campaign 'Get the Rich Look'

By IPP Bureau - July 17, 2025

The campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life.

Briefs: Godavari Biorefineries and Anuh Pharma
Briefs: Godavari Biorefineries and Anuh Pharma

By IPP Bureau - July 16, 2025

Godavari Biorefineries receives patent from CNIPA

Waters, BD biosciences unit agree to $17.5 billion merger
Waters, BD biosciences unit agree to $17.5 billion merger

By IPP Bureau - July 16, 2025

The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026

Latest Stories

Interviews

Packaging